Searched for
VIZAG API FACILITY
Lupin unit commissions oncology block at Vizag plant to expand CDMO bizDrug firm Lupin has commissioned a new oncology block at its Vizag manufacturing plant. This dedicated unit will boost contract development...- US FDA inspects Vishakhapatnam facility of Solara Active PharmaThe US Food and Drug Administration (FDA) completes inspection of Solara Active Pharma Sciences' API manufacturing facility in Visakhapatna...
- Kotak Fund to part finance matrix lab founder's Viatris buyThe fund plans to provide a $150 million mezzanine debt facility at 18-20% and arrange another $300 million from other lenders to finance t...
- Matrix Laboratories founder buys back API Biz from ViatrisNimmagadda Prasad, the founder of Matrix Laboratories, has bought back the active pharmaceutical ingredients (API) business he sold to Myla...
- Matrix Labs founder buys back Viatris' API business in IndiaViatris' latest transaction includes three manufacturing sites and a R&D lab in Hyderabad, three manufacturing sites in Vizag and third-par...
- Lupin's Vizag unit gets no observations from USFDA“We are pleased with the successful completion of the inspection at our Vizag facility. This accomplishment is a testament to our commitmen...
- Biocon's growth drivers are in place: 5 reasons it is this week's stock pickImproving prospects of the pharma industry, growth in the global generics market, expanded product portfolio and cost reduction initiatives...
- Aurobindo Pharma taps PEs for stake sale in injectable businessAs part of expanding the injectable business, Aurobindo is setting up a dedicated injectable facility in Vizag for the EU and other global ...
- Carlyle set to buy animal health company Sequent ScientificCarlyle is expected to first buy around 50% stake from the promoters and their families at Rs 85-90 a share, or a 7-10% premium to the curr...
- USFDA in active mode, issues obersvations to 4 drug makers in 3 days!SMS Pharma today informed exchanges that the United States Food and Drug Administration (USFDA) conducted a cGMP inspection at Kandivalasa,...
- Lupin gets 5 observations from USFDA for its Vizag facilityThe inspection of company's Vizag API manufacturing facility by the United States Food and Drug Administration (USFDA) has been completed, ...
- Divis to spend Rs 300 crore on expansion plans in 2018The company spent about Rs 400 crore till December last year and will be spending another Rs 300 crore on the expansion programme during th...
- SeQuent's arm Alivira gets USFDA nod for Visakhapatnam API facilityAlivira has received USFDA approval for its multi-product animal health API facility in Visakhapatnam, SeQuent Scientific said.
- Granules India's net profit up 26 pc to Rs 41 cr in Q2The company's revenue increased by 3 per cent at Rs 364 crore as compared to Rs 353 crore in the corresponding period.
- Torrent Pharma buys Glochem Unit in VizagET had reported in its May 27 edition that the two companies are in advanced talks for a possible transaction.
- We are marketing generics and will launch our own label soon: C Krishna Prasad, Granules IndiaGranules India is looking for a big start to generic business.
- USFDA observations relate to quality control testing: Saumen Chakraborty, Dr Reddy's"There are some API sales which have been happening. We are just getting all the numbers right."
- Shasun inks pact with SeQuent Scientific to form joint ventureSeQuent and Shasun will hold 73% and 27% stakes respectively in the firm, which is expected to be operational in the first quarter of 2014-...
- Shasun Pharmaceuticals aims to be Rs 2,000 cr company by 2015Shasun Pharmaceuticals today said it aims to achieve revenues of Rs 2,000 crore by the end of 2015.
- Tokyo's Eisai to invest Rs 500 cr in Vizag SEZTokyo-based pharma major Eisai has zoomed on India to set up a new Rs 500 crore manufacturing and R&D centre.
Load More
